Posts by Bryan D. Choi, MD, PhD
-
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Massachusetts General Hospital researchers have developed TanCART, the first chimeric antigen receptor T cell that targets EGFRvIII and IL-13R?2 simultaneously, and found it was effective in vitro and in murine models of heterogeneous glioblastoma, including patient-derived xenografts.
-
Designing Leading-Edge Immunotherapy for Brain Cancer
New immunotherapy for brain cancer tackles the barrier of tumor heterogeneity using a home-grown combination of CAR T-cell therapy and bispecific antibodies.
-
Review: Implications of IDH Mutations for Success of Glioma Immunotherapy
Neuroscience researchers at Massachusetts General Hospital recently reviewed the latest data on the tumor immune microenvironment of IDH-mutant glioma, the role of 2-hydroxyglutarate as a regulator of glioma immune evasion, and novel immunotherapeutic strategies that are being investigated in early clinical trials.
-
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
Biography
Bryan D. Choi, MD, PhD, is associate director of the Center for Brain Tumor Immunology and Immunotherapy and an attending neurosurgeon in the Department of Neurosurgery and the Stephen E. and Catherine Pappas Center for Neuro-Oncology at Massachusetts General Hospital. Dr. Choi is also an assistant professor of neurosurgery at Harvard Medical School.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.